Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Colorectal Neoplasms

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 76 articles:
HTML format
Text format



Single Articles


    March 2018
  1. TOLEDO RA, Garralda E, Mitsi M, Pons T, et al
    Exome sequencing of plasma DNA portrays the mutation landscape of colorectal cancer and discovers mutated VEGFR2 receptors as modulators of anti-angiogenic therapies.
    Clin Cancer Res. 2018 Mar 27. pii: 1078-0432.CCR-18-0103.
    PubMed     Text format     Abstract available


  2. MURCIA O, Jover R, Egoavil CM, Juarez M, et al
    TFAP2E Methylation and Expression Status Does Not Predict Response to 5FU-based Chemotherapy in Colorectal Cancer.
    Clin Cancer Res. 2018 Mar 13. pii: 1078-0432.CCR-17-2940.
    PubMed     Text format     Abstract available


  3. KANDIMALLA R, Gao F, Matsuyama T, Ishikawa T, et al
    Genome-wide discovery and identification of a novel miRNA signature for recurrence prediction in stage II and III colorectal cancer.
    Clin Cancer Res. 2018 Mar 7. pii: 1078-0432.CCR-17-3236.
    PubMed     Text format     Abstract available


  4. HILL AG, Findlay M, Burge M, Jackson C, et al
    Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer.
    Clin Cancer Res. 2018 Mar 5. pii: 1078-0432.CCR-17-0646.
    PubMed     Text format     Abstract available


    February 2018
  5. MESANGE P, Bouygues A, Ferrand N, Sabbah M, et al
    Combinations of Bevacizumab and Erlotinib show activity in colorectal cancer independent of RAS status.
    Clin Cancer Res. 2018 Feb 28. pii: 1078-0432.CCR-17-3187.
    PubMed     Text format     Abstract available


  6. HAYNES J, McKee TD, Haller AC, Wang Y, et al
    Administration of Hypoxia-Activated Prodrug Evofosfamide after Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Colorectal Cancer.
    Clin Cancer Res. 2018 Feb 23. pii: 1078-0432.CCR-17-1715.
    PubMed     Text format     Abstract available


  7. LI X, Wang Q, Gao X, Yu T, et al
    REGgamma controls Hippo signaling and reciprocal NF-kappaB-YAP regulation to promote colon cancer.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2986.
    PubMed     Text format     Abstract available


  8. LAMPRECHT S, Kaller M, Schmidt EM, Blaj C, et al
    PBX3 is part of an EMT regulatory network and indicates poor outcome in colorectal cancer.
    Clin Cancer Res. 2018 Feb 1. pii: 1078-0432.CCR-17-2572.
    PubMed     Text format     Abstract available


    January 2018

  9. Correction: Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
    Clin Cancer Res. 2018;24:499.
    PubMed     Text format    


    December 2017
  10. LIANG Q, Ma D, Zhu X, Wang Z, et al
    RING-finger protein 6 amplification activates JAK/STAT3 pathway by modifying SHP-1 ubiquitylation and associates with poor outcome in colorectal cancer.
    Clin Cancer Res. 2017 Dec 29. pii: 1078-0432.CCR-17-2133.
    PubMed     Text format     Abstract available


  11. DIENSTMANN R
    Tumor side as model of integrative molecular classification of colorectal cancer.
    Clin Cancer Res. 2017 Dec 21. pii: 1078-0432.CCR-17-3477.
    PubMed     Text format     Abstract available


  12. SVEEN A, Bruun J, Eide PW, Eilertsen IA, et al
    Colorectal cancer Consensus Molecular Subtypes translated to preclinical models uncover potentially targetable cancer-cell dependencies.
    Clin Cancer Res. 2017 Dec 14. pii: 1078-0432.CCR-17-1234.
    PubMed     Text format     Abstract available


  13. BERGER MD, Stintzing S, Heinemann V, Cao S, et al
    A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-1663.
    PubMed     Text format     Abstract available


  14. ULINTZ PJ, Greenson JK, Wu R, Fearon ER, et al
    Lymph Node Metastases in Colon Cancer are Polyclonal.
    Clin Cancer Res. 2017 Dec 4. pii: 1078-0432.CCR-17-1425.
    PubMed     Text format     Abstract available


  15. CARNERO A, Lucena-Cacace A, Otero-Albiol D, Jimenez-Garcia MP, et al
    NAMPT is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and resistance to therapy through Sirt1 and PARP.
    Clin Cancer Res. 2017 Dec 4. pii: 1078-0432.CCR-17-2575.
    PubMed     Text format     Abstract available


    November 2017
  16. LOREE JM, Pereira AA, Lam M, Willauer AN, et al
    Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-2484.
    PubMed     Text format     Abstract available


    October 2017
  17. GROTHEY A, Strosberg JR, Renfro LA, Hurwitz HI, et al
    A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Ontuxizumab (MORAb-004) in Patients with Chemorefractory Metastatic Colorectal Cancer.
    Clin Cancer Res. 2017 Oct 30. pii: clincanres.1558.2017.
    PubMed     Text format     Abstract available


  18. LAL N, White BS, Goussous G, Pickles OJ, et al
    KRAS mutation and Consensus Molecular Subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.1090.2017.
    PubMed     Text format     Abstract available


  19. BOCCACCIO C, Luraghi P, Bigatto V, Cipriano E, et al
    A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy.
    Clin Cancer Res. 2017 Oct 3. pii: clincanres.2151.2017.
    PubMed     Text format     Abstract available


    September 2017
  20. KANG DW, Lee BH, Suh YA, Choi YS, et al
    Phospholipase D1 inhibition linked to upregulation of ICAT blocks colorectal cancer growth hyperactivated by Wnt/beta-catenin and PI3K/Akt Signaling.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0749.2017.
    PubMed     Text format     Abstract available


  21. JOUNG JG, Oh BY, Hong HK, AlKhalidi H, et al
    Tumor heterogeneity predicts metastatic potential in colorectal cancer.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0306.2017.
    PubMed     Text format     Abstract available


  22. YIN Y, Yao S, Hu Y, Feng Y, et al
    The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-derived IL-6.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.1283.2017.
    PubMed     Text format     Abstract available


  23. BARTOLOME RA, Aizpurua C, Jaen M, Torres S, et al
    Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis.
    Clin Cancer Res. 2017 Sep 15. pii: clincanres.1444.2017.
    PubMed     Text format     Abstract available


  24. JIAO HL, Ye YP, Yang RW, Sun HY, et al
    Down-regulation of SAFB sustains the NF-kappaB pathway by targeting TAK1 during the progression of colorectal cancer.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0747.2017.
    PubMed     Text format     Abstract available


    August 2017
  25. SCURR MJ, Pembroke T, Bloom A, Roberts DJ, et al
    Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer.
    Clin Cancer Res. 2017 Aug 29. pii: clincanres.0895.2017.
    PubMed     Text format     Abstract available


    June 2017
  26. YAO YM, Donoho GP, Iversen P, Zhang Y, et al
    Mouse PDX Trial Suggests Synergy of concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS mutations.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.3250.2016.
    PubMed     Text format     Abstract available


  27. PEKOW J, Meckel K, Dougherty U, Huang Y, et al
    miR-193a-3p is a key tumor suppressor in ulcerative colitis-associated colon cancer and promotes carcinogenesis through up-regulation of IL17RD.
    Clin Cancer Res. 2017 Jun 9. pii: clincanres.0171.2017.
    PubMed     Text format     Abstract available


  28. SCHOLER LV, Reinert T, Orntoft MW, Kassentoft CG, et al
    Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer.
    Clin Cancer Res. 2017 Jun 9. pii: clincanres.0510.2017.
    PubMed     Text format     Abstract available


  29. PRIEUR A, Cappellini M, Habif G, Lefranc MP, et al
    Targeting the Wnt pathway and cancer stem cells with anti-progastrin humanized antibodies: a major breakthrough for K-RAS mutated colorectal cancer treatment.
    Clin Cancer Res. 2017 Jun 9. pii: clincanres.0533.2017.
    PubMed     Text format     Abstract available


  30. GARLAN F, Laurent-Puig P, Sefrioui D, Siauve N, et al
    Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study).
    Clin Cancer Res. 2017 Jun 2. pii: clincanres.3155.2016.
    PubMed     Text format     Abstract available


    May 2017
  31. STIEGELBAUER V, Vychytilova-Faltejskova P, Karbiener M, Pehserl AM, et al
    MicroRNA-196b-5p regulates colorectal cancer cell migration and metastases through interaction of HOXB7 and GALNT5.
    Clin Cancer Res. 2017 May 22. pii: clincanres.0023.2017.
    PubMed     Text format     Abstract available


  32. GOLDSTEIN JB, Wu W, Borras E, Masand G, et al
    Can Microsatellite Status of Colorectal Cancer be Reliably Assessed after Neoadjuvant Therapy?
    Clin Cancer Res. 2017 May 18. pii: clincanres.2994.2016.
    PubMed     Text format     Abstract available


    April 2017
  33. XU JM, Wang Y, Wang YL, Wang Y, et al
    PIK3CA mutations contribute to acquired cetuximab resistance in metastatic colorectal cancer patients.
    Clin Cancer Res. 2017 Apr 19. pii: clincanres.2738.2016.
    PubMed     Text format     Abstract available


  34. THIERRY AR, Pastor B, Jiang ZQ, Katsiampoura A, et al
    Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer.
    Clin Cancer Res. 2017 Apr 11. pii: clincanres.0232.2017.
    PubMed     Text format     Abstract available


    March 2017
  35. CARBONE C, Piro G, Simionato F, Ligorio F, et al
    Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients.
    Clin Cancer Res. 2017 Mar 15. pii: clincanres.3153.2016.
    PubMed     Text format     Abstract available


  36. PARSEGHIAN C, Parikh NU, Wu JY, Jiang ZQ, et al
    Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.3138.2016.
    PubMed     Text format     Abstract available


  37. PICHLER M, Stiegelbauer V, Vychytilova-Faltejskova P, Ivan C, et al
    Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis.
    Clin Cancer Res. 2017;23:1323-1333.
    PubMed     Text format     Abstract available


    February 2017
  38. WENG W, Wei Q, Toden S, Yoshida K, et al
    Circular RNA ciRS-7 - A promising prognostic biomarker and a potential therapeutic target in colorectal cancer.
    Clin Cancer Res. 2017 Feb 7. pii: clincanres.2541.2016.
    PubMed     Text format     Abstract available


    January 2017
  39. GOVERNA V, Trella E, Mele V, Tornillo L, et al
    The interplay between neutrophils and CD8+ T cells improves survival in human colorectal cancer.
    Clin Cancer Res. 2017 Jan 20. pii: clincanres.2047.2016.
    PubMed     Text format     Abstract available


    November 2016
  40. BLAJ C, Bringmann A, Schmidt EM, Urbischek M, et al
    ADNP is a therapeutically inducible repressor of WNT signaling in colorectal cancer.
    Clin Cancer Res. 2016 Nov 30. pii: clincanres.1604.2016.
    PubMed     Text format     Abstract available


  41. SUMMERS M, Smith CG, Maughan TS, Kaplan R, et al
    BRAF and NRAS locus specific variants have different outcomes on survival to colorectal cancer.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1541.2016.
    PubMed     Text format     Abstract available


    October 2016
  42. PIETRANTONIO F, Vernieri C, Siravegna G, Mennitto A, et al
    Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer.
    Clin Cancer Res. 2016 Oct 25. pii: clincanres.1863.2016.
    PubMed     Text format     Abstract available


  43. LIANG JQ, Chiu J, Chen Y, Huang Y, et al
    Fecal Bacteria Act as Novel Biomarkers for Non-Invasive Diagnosis of Colorectal Cancer.
    Clin Cancer Res. 2016 Oct 3. pii: clincanres.1599.2016.
    PubMed     Text format     Abstract available


  44. NEGRI FV, Boggiani D, Rimanti A, Musolino A, et al
    FCGR, Cetuximab, and Colorectal Cancer Survival-Letter.
    Clin Cancer Res. 2016;22:4958.
    PubMed     Text format    


    September 2016
  45. MA Y, Wang L, Neitzel LR, Loganathan S, et al
    The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.0453.2016.
    PubMed     Text format     Abstract available


  46. PARK JH, Van Wyk HC, McMillan DC, Quinn JA, et al
    Signal transduction and activator of transcription-3 (STAT3) in patients with colorectal cancer: associations with the phenotypic features of the tumour and host.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.1416.2016.
    PubMed     Text format     Abstract available


  47. SALVUCCI M, Wurstle ML, Morgan C, Curry S, et al
    A stepwise integrated approach to personalized risk predictions in stage III colorectal cancer.
    Clin Cancer Res. 2016 Sep 20. pii: clincanres.1084.2016.
    PubMed     Text format     Abstract available


    August 2016
  48. SHIGEYASU K, Okugawa Y, Toden S, Boland CR, et al
    Exportin-5 functions as an oncogene and a potential therapeutic target in colorectal cancer.
    Clin Cancer Res. 2016 Aug 23. pii: clincanres.1023.2016.
    PubMed     Text format     Abstract available


  49. WEI TT, Lin YT, Tseng RY, Shun CT, et al
    Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
    Clin Cancer Res. 2016;22:4158-69.
    PubMed     Text format     Abstract available


  50. TOFFOLI G, Sharma MR, Marangon E, Posocco B, et al
    Genotype-guided dosing study of FOLFIRI plus bevacizumab in metastatic colorectal cancer patients.
    Clin Cancer Res. 2016 Aug 9. pii: clincanres.1012.2016.
    PubMed     Text format     Abstract available


  51. YAMAMOTO T, Kawada K, Itatani Y, Inamoto S, et al
    Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-associated Neutrophils through CCL15-CCR1 Axis.
    Clin Cancer Res. 2016 Aug 4. pii: clincanres.0520.2016.
    PubMed     Text format     Abstract available


  52. MUSTAFI R, Dougherty U, Mustafi D, Ayaloglu-Butun F, et al
    ADAM17 is a tumor promoter and therapeutic target in Western diet-associated colon cancer.
    Clin Cancer Res. 2016 Aug 3. pii: clincanres.3140.2016.
    PubMed     Text format     Abstract available



  53. Correction: MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    Clin Cancer Res. 2016;22:3982.
    PubMed     Text format    


    July 2016
  54. TRINH A, Trumpi K, de Sousa E Melo F, Wang X, et al
    Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry.
    Clin Cancer Res. 2016 Jul 26. pii: clincanres.0680.2016.
    PubMed     Text format     Abstract available


  55. QIAN DC, Xiao X, Byun J, Suriawinata AA, et al
    PI3K/Akt/mTOR signaling and plasma membrane proteins are implicated in responsiveness to adjuvant dendritic cell vaccination for metastatic colorectal cancer.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0623.2016.
    PubMed     Text format     Abstract available


  56. DE ROBERTIS M, Loiacono L, Fusilli C, Poeta LM, et al
    Dysregulation of EGFR pathway in EphA2 cell subpopulation significantly associates with poor prognosis in colorectal cancer.
    Clin Cancer Res. 2016 Jul 11. pii: clincanres.0709.2016.
    PubMed     Text format     Abstract available


  57. BENSON AB, Kiss I, Bridgewater J, Eskens FA, et al
    BATON-CRC: a phase II randomized trial comparing tivozanib plus mFOLFOX6 with bevacizumab plus mFOLFOX6 in stage IV metastatic colorectal cancer.
    Clin Cancer Res. 2016 Jul 11. pii: clincanres.3117.2016.
    PubMed     Text format     Abstract available


    June 2016
  58. BARRAS D, Missiaglia E, Wirapati P, Sieber OM, et al
    BRAF V600E mutant colorectal cancer subtypes based on gene expression.
    Clin Cancer Res. 2016 Jun 27. pii: clincanres.0140.2016.
    PubMed     Text format     Abstract available


  59. KUROIWA-TRZMIELINA J, Wang F, Rapkins RW, Ward RL, et al
    SNP rs16906252C>T is an expression and methylation quantitative trait locus associated with an increased risk of developing MGMT-methylated colorectal cancer.
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.2765.2015.
    PubMed     Text format     Abstract available


    May 2016
  60. LIU G, Tu D, Lewis M, Cheng D, et al
    Fc-gamma Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.
    Clin Cancer Res. 2016;22:2435-44.
    PubMed     Text format     Abstract available


  61. MUNAKATA K, Uemura M, Tanaka S, Kawai K, et al
    Cancer stem-like properties in colorectal cancer cells with low proteasome activity.
    Clin Cancer Res. 2016 May 10. pii: clincanres.1945.2015.
    PubMed     Text format     Abstract available


  62. WENG W, Okugawa Y, Toden S, Toiyama Y, et al
    FOXM1 and FOXQ1 are promising prognostic biomarkers and novel targets of tumor suppressive miR-342 in human colorectal cancer.
    Clin Cancer Res. 2016 May 9. pii: clincanres.0360.2016.
    PubMed     Text format     Abstract available


  63. DUNNE PD, McArt DG, Bradley CA, O'Reilly PG, et al
    Challenging the cancer molecular stratification dogma: Intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer.
    Clin Cancer Res. 2016 May 5. pii: clincanres.0032.2016.
    PubMed     Text format     Abstract available


    April 2016
  64. MEYN RE, Krishnan S, Skinner HD
    Everything Old Is New Again: Using Nelfinavir to Radiosensitize Rectal Cancer.
    Clin Cancer Res. 2016;22:1834-6.
    PubMed     Text format     Abstract available


  65. HILL EJ, Roberts C, Franklin JM, Enescu M, et al
    Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer.
    Clin Cancer Res. 2016;22:1922-31.
    PubMed     Text format     Abstract available


  66. FERREIRO-NEIRA I, Torres NE, Liesenfeld LF, Chan CH, et al
    XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer.
    Clin Cancer Res. 2016;22:1663-73.
    PubMed     Text format     Abstract available


    February 2016
  67. DUDLEY JC, Lin MT, Le DT, Eshleman JR, et al
    Microsatellite Instability as a Biomarker for PD-1 Blockade.
    Clin Cancer Res. 2016;22:813-20.
    PubMed     Text format     Abstract available


  68. MEULENDIJKS D, Jacob W, Martinez-Garcia M, Taus A, et al
    First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.
    Clin Cancer Res. 2016;22:877-85.
    PubMed     Text format     Abstract available


  69. PATNAIK A, Weiss GJ, Leonard JE, Rasco DW, et al
    Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors.
    Clin Cancer Res. 2016;22:827-36.
    PubMed     Text format     Abstract available


  70. MEULENDIJKS D, Lassen UN, Siu LL, Huitema AD, et al
    Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.
    Clin Cancer Res. 2016;22:858-67.
    PubMed     Text format     Abstract available


  71. SCHELL MJ, Yang M, Missiaglia E, Delorenzi M, et al
    A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.
    Clin Cancer Res. 2016;22:734-45.
    PubMed     Text format     Abstract available


  72. XU L, Ziegelbauer J, Wang R, Wu WW, et al
    Distinct Profiles for Mitochondrial t-RNAs and Small Nucleolar RNAs in Locally Invasive and Metastatic Colorectal Cancer.
    Clin Cancer Res. 2016;22:773-84.
    PubMed     Text format     Abstract available


  73. ARQUES O, Chicote I, Puig I, Tenbaum SP, et al
    Tankyrase Inhibition Blocks Wnt/beta-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Clin Cancer Res. 2016;22:644-56.
    PubMed     Text format     Abstract available


    January 2016
  74. ZIEMKE EK, Dosch JS, Maust JD, Shettigar A, et al
    Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.
    Clin Cancer Res. 2016;22:405-14.
    PubMed     Text format     Abstract available


  75. TURKSMA AW, Coupe VM, Shamier MC, Lam KL, et al
    Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy.
    Clin Cancer Res. 2016;22:346-56.
    PubMed     Text format     Abstract available


  76. INAMOTO S, Itatani Y, Yamamoto T, Minamiguchi S, et al
    Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15-CCR1 Chemokine Axis.
    Clin Cancer Res. 2016;22:492-501.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: